• 1
    Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998; 95: 1336383
  • 2
    Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 2001; 24: 51950
  • 3
    Weissmann C. The state of the prion. Nat Rev Microbiol 2004; 2: 86171
  • 4
    Caughey B, Baron GS. Prions and their partners in crime. Nature 2006; 443: 80310
  • 5
    Collinge J, Clarke A. A general model of prion strains and their pathogenicity. Science 2007; 318: 9306
  • 6
    Griffith JS. Self replication and scrapie. Nature 1967; 215: 10434
  • 7
    Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216: 13644
  • 8
    Riesner D. Biochemistry and structure of PrP(C) and PrP(Sc). Br Med Bull 2003; 66: 2133
  • 9
    Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, Caughey B. The most infectious prion protein particles. Nature 2005; 437: 25761
  • 10
    Deleault NR, Harris BT, Rees JR, Supattapone S. Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A 2007; 104: 97416
  • 11
    Geoghegan JC, Valdes PA, Orem NR, Deleault NR, Williamson RA, Harris BT, Supattapone S. Selective incorporation of polyanionic molecules into hamster prions. J Biol Chem 2007; 282: 3634153
  • 12
    Wang F, Wang X, Yuan CG, Ma J. Generating a prion with bacterially expressed recombinant prion protein. Science 2010; 327: 11325
  • 13
    Supattapone S. What makes a prion infectious? Science 2010; 327: 10912
  • 14
    Collinge J. Variant Creutzfeldt-Jakob disease. Lancet 1999; 354: 31723
  • 15
    Shorter J, Lindquist S. Prions as adaptive conduits of memory and inheritance. Nat Rev Genet 2005; 6: 43550
  • 16
    Tanaka M, Chien P, Yonekura K, Weissman JS. Mechanism of cross-species prion transmission an infectious conformation compatible with two highly divergent yeast prion proteins. Cell 2005; 121: 4962
  • 17
    Wickner RB, Edskes HK, Shewmaker F, Nakayashiki T. Prions of fungi: inherited structures and biological roles. Nat Rev Microbiol 2007; 5: 61118
  • 18
    Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 2005; 307: 2625
  • 19
    Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006; 313: 17814
  • 20
    Olanow CW, Prusiner SB. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A 2009; 106: 125712
  • 21
    Miller G. Neurodegeneration. Could they all be prion diseases? Science 2009; 326: 13379
  • 22
    Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 4869
  • 23
    Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009; 457: 112832
  • 24
    Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 9215
  • 25
    Collinge J, Sidle KC, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 1996; 383: 68590
  • 26
    Hill AF, Desbruslais M, Joiner S, Sidle KCL, Gowland I, Collinge J. The same prion strain causes vCJD and BSE. Nature 1997; 389: 44850
  • 27
    Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, McCardle L, Chree A, Hope J, Birkett C, Cousens S, Fraser H, Bostock CJ. Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 1997; 389: 498501
  • 28
    Asante E, Linehan J, Desbruslais M, Joiner S, Gowland I, Wood A, Welch J, Hill AF, Lloyd S, Wadsworth JD, Collinge J. BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J 2002; 21: 635866
  • 29
    Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Ritchie D, Penney M, Hegazy D, Ironside JW. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004; 203: 7339
  • 30
    Frosh A, Smith LC, Jackson CJ, Linehan J, Brandner S, Wadsworth JD, Collinge J. Analysis of 2000 consecutive UK tonsillectomy specimens for disease-related prion protein. Lancet 2004; 364: 12602
  • 31
    Hilton DA. Pathogenesis and prevalence of variant Creutzfeldt-Jakob disease. J Pathol 2005; 208: 13441
  • 32
    Collinge J, Whitfield J, McKintosh E, Beck J, Mead S, Thomas DJ, Alpers MP. Kuru in the 21st century-an acquired human prion disease with very long incubation periods. Lancet 2006; 367: 206874
  • 33
    Wadsworth JD, Collinge J. Update on human prion disease. Biochim Biophys Acta 2007; 1772: 598609
  • 34
    Wadsworth JD, Joiner S, Hill AF, Campbell TA, Desbruslais M, Luthert PJ, Collinge J. Tissue distribution of protease resistant prion protein in variant CJD using a highly sensitive immuno-blotting assay. Lancet 2001; 358: 17180
  • 35
    Joiner S, Linehan J, Brandner S, Wadsworth JD, Collinge J. Irregular presence of abnormal prion protein in appendix in variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2002; 73: 5978
  • 36
    Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, Will RG. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 41721
  • 37
    Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364: 5279
  • 38
    Wroe SJ, Pal S, Siddique D, Hyare H, Macfarlane R, Joiner S, Linehan J, Brandner S, Wadsworth JD, Hewitt P, Collinge J. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006; 368: 20617
  • 39
    Collinge J. Molecular neurology of prion disease. J Neurol Neurosurg Psychiatry 2005; 76: 90619
  • 40
    Peden A, McCardle L, Head MW, Love S, Ward HJ, Cousens SN, Keeling DM, Millar CM, Hill FG, Ironside JW. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16: 296304
  • 41
    Kong Q, Zheng M, Casalone C, Qing L, Huang S, Chakraborty B, Wang P, Chen F, Cali I, Corona C, Martucci F, Iulini B, Acutis P, Wang L, Liang J, Wang M, Li X, Monaco S, Zanusso G, Zou WQ, Caramelli M, Gambetti P. Evaluation of the human transmission risk of an atypical bovine spongiform encephalopathy prion strain. J Virol 2008; 82: 3697701
  • 42
    Beringue V, Andreoletti O, Le Dur A, Essalmani R, Vilotte JL, Lacroux C, Reine F, Herzog L, Biacabe AG, Baron T, Caramelli M, Casalone C, Laude H. A bovine prion acquires an epidemic bovine spongiform encephalopathy strain-like phenotype on interspecies transmission. J Neurosci 2007; 27: 696571
  • 43
    Beringue V, Vilotte JL, Laude H. Prion agents diversity and species barrier. Vet Res 2008; 39: 47
  • 44
    Beringue V, Herzog L, Reine F, Le Dur A, Casalone C, Vilotte JL, Laude H. Transmission of atypical bovine prions to mice transgenic for human prion protein. Emerg Infect Dis 2008; 14: 1898901
  • 45
    Baron T, Biacabe AG, Arsac JN, Benestad S, Groschup MH. Atypical transmissible spongiform encephalopathies (TSEs) in ruminants. Vaccine 2007; 25: 562530
  • 46
    Benestad SL, Arsac JN, Goldmann W, Noremark M. Atypical/Nor98 scrapie: properties of the agent, genetics, and epidemiology. Vet Res 2008; 39: 19
  • 47
    Castilla J, Gonzalez-Romero D, Saa P, Morales R, De Castro J, Soto C. Crossing the species barrier by PrP(Sc) replication in vitro generates unique infectious prions. Cell 2008; 134: 75768
  • 48
    Lloyd S, Linehan J, Desbruslais M, Joiner S, Buckell J, Brandner S, Wadsworth JD, Collinge J. Characterization of two distinct prion strains derived from bovine spongiform encephalopathy transmissions to inbred mice. J Gen Virol 2004; 85: 24718
  • 49
    Wadsworth JD, Asante EA, Desbruslais M, Linehan J, Joiner S, Gowland I, Welch J, Stone L, Lloyd S, Hill AF, Brandner S, Collinge J. Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science 2004; 306: 17936
  • 50
    Mead S, Poulter M, Uphill J, Beck J, Whitfield J, Webb TE, Campbell T, Adamson G, Deriziotis P, Tabrizi SJ, Hummerich H, Verzilli C, Alpers MP, Whittaker JC, Collinge J. Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol 2009; 8: 5766
  • 51
    Lloyd SE, Maytham EG, Pota H, Grizenkova J, Molou E, Uphill J, Hummerich H, Whitfield J, Alpers MP, Mead S, Collinge J. HECTD2 is associated with susceptibility to mouse and human prion disease. PLoS Genet 2009; 5: e1000383
  • 52
    Hill AF, Collinge J. Subclinical prion infection. Trends Microbiol 2003; 11: 57884
  • 53
    Taylor DM. Resistance of transmissible spongiform encephalopathy agents to decontamination. Contrib Microbiol 2004; 11: 13645
  • 54
    Jackson GS, McKintosh E, Flechsig E, Prodromidou K, Hirsch P, Linehan J, Brandner S, Clarke A, Weissmann C, Collinge J. An enzyme-detergent method for effective prion decontamination of surgical steel. J Gen Virol 2005; 86: 86978
  • 55
    Gajdusek DC, Gibbs CJJr, Alpers M. Experimental transmission of a kuru-like syndrome to chimpanzees. Nature 1966; 209: 7946
  • 56
    Gibbs CJJr, Gajdusek DC, Asher DM, Alpers MP, Beck E, Daniel PM, Matthews WB. Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science 1968; 161: 3889
  • 57
    Brown P, Gibbs CJJr, Rodgers Johnson P, Asher DM, Sulima MP, Bacote A, Goldfarb LG, Gajdusek DC. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994; 35: 51329
  • 58
    Collinge J, Palmer MS, Sidle KCL, Hill AF, Gowland I, Meads J, Asante EA, Bradley R, Doey LJ, Lantos PL. Unaltered susceptibility to BSE in transgenic mice expressing human prion protein. Nature 1995; 378: 77983
  • 59
    Telling GC, Scott M, Mastrianni J, Gabizon R, Torchia M, Cohen FE, DeArmond SJ, Prusiner SB. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 1995; 83: 7990
  • 60
    Asante E, Collinge J. Transgenic studies of the influence of the PrP structure on TSE diseases. Adv Protein Chem 2001; 57: 273311
  • 61
    Manson JC, Tuzi NL. Transgenic models of the transmissible spongiform encephalopathies. Expert Rev Mol Med 2001; 2001: 115
  • 62
    Weissmann C, Flechsig E. PrP knock-out and PrP transgenic mice in prion research. Br Med Bull 2003; 66: 4360
  • 63
    Bishop MT, Hart P, Aitchison L, Baybutt HN, Plinston C, Thomson V, Tuzi NL, Head MW, Ironside JW, Will RG, Manson JC. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol 2006; 5: 3938
  • 64
    Groschup MH, Buschmann A. Rodent models for prion diseases. Vet Res 2008; 39: 32
  • 65
    Telling GC. Transgenic mouse models of prion diseases. Methods Mol Biol 2008; 459: 24963
  • 66
    Wadsworth JD, Hill AF, Beck J, Collinge J. Molecular and clinical classification of human prion disease. Br Med Bull 2003; 66: 24154
  • 67
    Mead S. Prion disease genetics. Eur J Hum Genet 2006; 14: 27381
  • 68
    Collinge J, Harding AE, Owen F, Poulter M, Lofthouse R, Boughey AM, Shah T, Crow TJ. Diagnosis of Gerstmann-Straussler syndrome in familial dementia with prion protein gene analysis. Lancet 1989; 2: 1517
  • 69
    Collinge J, Owen F, Poulter M, Leach M, Crow TJ, Rossor MN, Hardy J, Mullan MJ, Janota I, Lantos PL. Prion dementia without characteristic pathology. Lancet 1990; 336: 79
  • 70
    Collinge J, Brown J, Hardy J, Mullan M, Rossor MN, Baker H, Crow TJ, Lofthouse R, Poulter M, Ridley R, Owen F, Bennett C, Dunn G, Harding AE, Quinn N, Doshi B, Roberts GW, Honavar M, Janota I, Lantos PL. Inherited prion disease with 144 base pair gene insertion: II: clinical and pathological features. Brain 1992; 115: 687710
  • 71
    Mallucci G, Campbell TA, Dickinson A, Beck J, Holt M, Plant G, De Pauw KW, Hakin RN, Clarke CE, Howell S, Davies-Jones GAB, Lawden M, Smith CML, Ince P, Ironside JW, Bridges LR, Dean A, Weeks I, Collinge J. Inherited prion disease with an alanine to valine mutation at codon 117 in the prion protein gene. Brain 1999; 122: 182337
  • 72
    Kovacs GG, Trabattoni G, Hainfellner JA, Ironside JW, Knight RS, Budka H. Mutations of the prion protein gene phenotypic spectrum. J Neurol 2002; 249: 156782
  • 73
    Mead S, Poulter M, Beck J, Webb T, Campbell T, Linehan J, Desbruslais M, Joiner S, Wadsworth JD, King A, Lantos P, Collinge J. Inherited prion disease with six octapeptide repeat insertional mutation-molecular analysis of phenotypic heterogeneity. Brain 2006; 129: 2297317
  • 74
    Wadsworth JD, Joiner S, Linehan J, Cooper S, Powell C, Mallinson G, Buckell J, Gowland I, Asante EA, Budka H, Brandner S, Collinge J. Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein. Brain 2006; 129: 155769
  • 75
    Collinge J, Whitfield J, McKintosh E, Frosh A, Mead S, Hill AF, Brandner S, Thomas D, Alpers MP. A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea. Philos Trans R Soc Lond B Biol Sci 2008; 363: 372539
  • 76
    WHO. WHO Manual for Surveillance of Human Transmissible Spongiform Encephalopathies. Geneva: World Health Organisation Press, 2003
  • 77
    Budka H, Aguzzi A, Brown P, Brucher JM, Bugiani O, Gullotta F, Haltia M, Hauw JJ, Ironside JW, Jellinger K, Kretzschmar HA, Lantos PL, Masullo C, Schlote W, Tateishi J, Weller RO. Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (Prion diseases). Brain Pathol 1995; 5: 45966
  • 78
    Ironside JW, Head MW, Bell JE, McCardle L, Will RG. Laboratory diagnosis of variant Creutzfeldt-Jakob disease. Histopathology 2000; 37: 19
  • 79
    Wadsworth JD, Powell C, Beck JA, Joiner S, Linehan JM, Brandner S, Mead S, Collinge J. Molecular diagnosis of human prion disease. Methods Mol Biol 2008; 459: 197227
  • 80
    Collinge J, Palmer MS, Dryden AJ. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 1991; 337: 14412
  • 81
    Palmer MS, Dryden AJ, Hughes JT, Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 1991; 352: 3402
  • 82
    Windl O, Dempster M, Estibeiro JP, Lathe R, De Silva R, Esmonde T, Will R, Springbett A, Campbell TA, Sidle KCL, Palmer MS, Collinge J. Genetic basis of Creutzfeldt-Jakob disease in the United Kingom: a systematic analysis of predisposing mutations and allelic variation in the PRNP gene. Hum Genet 1996; 98: 25964
  • 83
    Lee HS, Brown P, Cervenáková L, Garruto RM, Alpers MP, Gajdusek DC, Goldfarb LG. Increased susceptibility to Kuru of carriers of the PRNP 129 methionine/methionine genotype. J Infect Dis 2001; 183: 1926
  • 84
    Mead S, Stumpf MP, Whitfield J, Beck J, Poulter M, Campbell T, Uphill J, Goldstein D, Alpers MP, Fisher E, Collinge J. Balancing selection at the prion protein gene consistent with prehistoric kuru-like epidemics. Science 2003; 300: 6403
  • 85
    Collins SJ, Sanchez-Juan P, Masters CL, Klug GM, Van Duijn C, Poleggi A, Pocchiari M, Almonti S, Cuadrado-Corrales N, Pedro-Cuesta J, Budka H, Gelpi E, Glatzel M, Tolnay M, Hewer E, Zerr I, Heinemann U, Kretszchmar HA, Jansen GH, Olsen E, Mitrova E, Alperovitch A, Brandel JP, Mackenzie J, Murray K, Will RG. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain 2006; 129: 227887
  • 86
    Bruce ME. TSE strain variation. Br Med Bull 2003; 66: 99108
  • 87
    Budka H. Neuropathology of prion diseases. Br Med Bull 2003; 66: 12130
  • 88
    Hainfellner JA, Brantner-Inthaler S, Cervenáková L, Brown P, Kitamoto T, Tateishi J, Diringer H, Liberski PP, Regele H, Feucht R, Mayr N, Wessely P, Summer K, Seitelberger F, Budka H. The original Gerstmann-Straussler-Scheinker family of Austria: divergent clinicopathological phenotypes but constant PrP genotype. Brain Pathol 1995; 5: 20111
  • 89
    Brandner S, Whitfield J, Boone K, Puwa A, O'Malley C, Linehan JM, Joiner S, Scaravilli F, Calder I, Alpers P, Wadsworth JD, Collinge J. Central and peripheral pathology of kuru: pathological analysis of a recent case and comparison with other forms of human prion disease. Philos Trans R Soc Lond B Biol Sci 2008; 363: 375563
  • 90
    Hill AF, Joiner S, Wadsworth JD, Sidle KC, Bell JE, Budka H, Ironside JW, Collinge J. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain 2003; 126: 133346
  • 91
    Ironside JW, Head MW. Neuropathology and molecular biology of variant Creutzfeldt-Jakob disease. Curr Top Microbiol Immunol 2004; 284: 13359
  • 92
    Telling GC, Parchi P, DeArmond SJ, Cortelli P, Montagna P, Gabizon R, Mastrianni J, Lugaresi E, Gambetti P, Prusiner SB. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 1996; 274: 207982
  • 93
    Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, Zerr I, Budka H, Kopp N, Piccardo P, Poser S, Rojiani A, Streichenberger N, Julien J, Vital C, Ghetti B, Gambetti P, Kretzschmar H. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999; 46: 22433
  • 94
    Safar J, Wille H, Itri V, Groth D, Serban H, Torchia M, Cohen FE, Prusiner SB. Eight prion strains have PrPSc molecules with different conformations. Nat Med 1998; 4: 115765
  • 95
    Castilla J, Morales R, Saa P, Barria M, Gambetti P, Soto C. Cell-free propagation of prion strains. EMBO J 2008; 27: 255766
  • 96
    Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, Farlow M, Dickson DW, Sims AAF, Trojanowski JQ, Petersen RB, Gambetti P. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1996; 39: 76778
  • 97
    Zanusso G, Farinazzo A, Fiorini M, Gelati M, Castagna A, Righetti PG, Rizzuto N, Monaco S. pH-dependent prion protein conformation in classical Creutzfeldt-Jakob disease. J Biol Chem 2001; 276: 4037780
  • 98
    Cali I, Castellani R, Yuan J, Al Shekhlee A, Cohen ML, Xiao X, Moleres FJ, Parchi P, Zou WQ, Gambetti P. Classification of sporadic Creutzfeldt-Jakob disease revisited. Brain 2006; 129: 226677
  • 99
    Gambetti P, Dong Z, Yuan J, Xiao X, Zheng M, Alshekhlee A, Castellani R, Cohen M, Barria MA, Gonzalez-Romero D, Belay ED, Schonberger LB, Marder K, Harris C, Burke JR, Montine T, Wisniewski T, Dickson DW, Soto C, Hulette CM, Mastrianni JA, Kong Q, Zou WQ. A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol 2008; 63: 697708
  • 100
    Parchi P, Notari S, Weber P, Schimmel H, Budka H, Ferrer I, Haik S, Hauw JJ, Head MW, Ironside JW, Limido L, Rodriguez A, Strobel T, Tagliavini F, Inter-Laboratory KHA. Assessment of PrP(Sc) Typing in Creutzfeldt-Jakob disease: a western blot study within the NeuroPrion consortium. Brain Pathol 2008; 19: 38491
  • 101
    Wadsworth JD, Hill AF, Joiner S, Jackson GS, Clarke A, Collinge J. Strain-specific prion-protein conformation determined by metal ions. Nat Cell Biol 1999; 1: 559
  • 102
    Uro-Coste E, Cassard H, Simon S, Lugan S, Bilheude JM, Perret-Liaudet A, Ironside JW, Haik S, Basset-Leobon C, Lacroux C, Peoch K, Streichenberger N, Langeveld J, Head MW, Grassi J, Hauw JJ, Schelcher F, Delisle MB, Andreoletti O. Beyond PrP type 1/type 2 dichotomy in Creutzfeldt-Jakob disease. PLoS Pathog 2008; 4: e1000029
  • 103
    Piccardo P, Dlouhy SR, Lievens PMJ, Young K, Bird TD, Nochlin D, Dickson DW, Vinters HV, Zimmerman TR, Mackenzie IRA, Kish SJ, Ang LC, De Carli C, Pocchiari M, Brown P, Gibbs CJ, Gajdusek DC, Bugiani O, Ironside J, Tagliavini F, Ghetti B. Phenotypic variability of Gerstmann-Straussler-Scheinker disease is associated with prion protein heterogeneity. J Neuropathol Exp Neurol 1998; 57: 97988
  • 104
    Puoti G, Giaccone G, Rossi G, Canciani B, Bugiani O, Tagliavini F. Sporadic Creutzfeldt-Jakob disease: co-occurrence of different types of PrPSc in the same brain. Neurology 1999; 53: 21736
  • 105
    Head MW, Bunn TJ, Bishop MT, McLoughlin V, Lowrie S, McKimmie CS, Williams MC, McCardle L, Mackenzie J, Knight R, Will RG, Ironside JW. Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob disease: U.K. cases 1991–2002. Ann Neurol 2004; 55: 8519
  • 106
    Polymenidou M, Stoeck K, Glatzel M, Vey M, Bellon A, Aguzzi A. Coexistence of multiple PrP(Sc) types in individuals with Creutzfeldt-Jakob disease. Lancet Neurol 2005; 4: 80514
  • 107
    Schoch G, Seeger H, Bogousslavsky J, Tolnay M, Janzer RC, Aguzzi A, Glatzel M. Analysis of prion strains by PrP(Sc) profiling in sporadic Creutzfeldt-Jakob disease. PLoS Med 2005; 3: e14
  • 108
    Yull HM, Ritchie DL, Langeveld JP, Van Zijderveld FG, Bruce ME, Ironside JW, Head MW. Detection of type 1 prion protein in variant Creutzfeldt-Jakob disease. Am J Pathol 2006; 168: 1517
  • 109
    Tzaban S, Friedlander G, Schonberger O, Horonchik L, Yedidia Y, Shaked G, Gabizon R, Taraboulos A. Protease-sensitive scrapie prion protein in aggregates of heterogeneous sizes. Biochemistry 2002; 41: 1286875
  • 110
    Tremblay P, Ball HL, Kaneko K, Groth D, Hegde RS, Cohen FE, DeArmond SJ, Prusiner SB, Safar JG. Mutant PrP(Sc) conformers induced by a synthetic peptide and several prion strains. J Virol 2004; 78: 208899
  • 111
    Safar JG, Geschwind MD, Deering C, Didorenko S, Sattavat M, Sanchez H, Serban A, Vey M, Baron H, Giles K, Miller BL, DeArmond SJ, Prusiner SB. Diagnosis of human prion disease. Proc Natl Acad Sci U S A 2005; 102: 35016
  • 112
    Nazor KE, Kuhn F, Seward T, Green M, Zwald D, Purro M, Schmid J, Biffiger K, Power AM, Oesch B, Raeber AJ, Telling GC. Immunodetection of disease-associated mutant PrP, which accelerates disease in GSS transgenic mice. EMBO J 2005; 24: 247280
  • 113
    Thackray AM, Hopkins L, Bujdoso R. Proteinase K-sensitive disease-associated ovine prion protein revealed by conformation-dependent immunoassay. Biochem J 2007; 401: 47583
  • 114
    Barron RM, Campbell SL, King D, Bellon A, Chapman KE, Williamson RA, Manson JC. High titres of TSE infectivity associated with extremely low levels of PrPSc in vivo. J Biol Chem 2007; 282: 3587886
  • 115
    Cronier S, Gros N, Tattum MH, Jackson GS, Clarke AR, Collinge J, Wadsworth JD. Detection and characterization of proteinase K-sensitive disease-related prion protein with thermolysin. Biochem J 2008; 416: 297305
  • 116
    Colby DW, Wain R, Baskakov IV, Legname G, Palmer CG, Nguyen HO, Lemus A, Cohen FE, DeArmond SJ, Prusiner SB. Protease-sensitive synthetic prions. PLoS Pathog 2010; 6: e1000736
  • 117
    Stephenson DA, Chiotti K, Ebeling C, Groth D, DeArmond SJ, Prusiner SB, Carlson GA. Quantitative trait loci affecting prion incubation time in mice. Genomics 2000; 69: 4753
  • 118
    Lloyd S, Onwuazor ON, Beck J, Mallinson G, Farrall M, Targonski P, Collinge J, Fisher E. Identification of multiple quantitative trait loci linked to prion disease incubation period in mice. Proc Natl Acad Sci U S A 2001; 98: 627983
  • 119
    Lloyd S, Collinge J. Genetic susceptibility to prion diseases in humans and mice. Current Genomics 2005; 6: 111
  • 120
    Brown P, Preece M, Brandel JP, Sato T, McShane L, Zerr I, Fletcher A, Will RG, Pocchiari M, Cashman NR, D'Aignaux JH, Cervenáková L, Fradkin J, Schonberger LB, Collins SJ. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2000; 55: 107581
  • 121
    Will RG. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull 2003; 66: 25565
  • 122
    Wadsworth JD, Joiner S, Linehan JM, Desbruslais M, Fox K, Cooper S, Cronier S, Asante EA, Mead S, Brandner S, Hill AF, Collinge J. Kuru prions and sporadic Creutzfeldt-Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proc Natl Acad Sci U S A 2008; 105: 388590
  • 123
    Wadsworth JD, Joiner S, Linehan JM, Asante EA, Brandner S, Collinge J. Review. The origin of the prion agent of kuru: molecular and biological strain typing. Philos Trans R Soc Lond B Biol Sci 2008; 363: 374753
  • 124
    Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, Weissmann C. Mice devoid of PrP are resistant to scrapie. Cell 1993; 73: 133947
  • 125
    Sailer A, Bueler H, Fischer M, Aguzzi A, Weissmann C. No propagation of prions in mice devoid of PrP. Cell 1994; 77: 9678
  • 126
    Scott MRD, Telling GC, Prusiner SB. Transgenetics and gene targeting in studies of prion diseases. Curr Top Microbiol Immunol 1996; 207: 95123
  • 127
    Fischer M, Rulicke T, Raeber A, Sailer A, Moser M, Oesch B, Brandner S, Aguzzi A, Weissmann C. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J 1996; 15: 125564
  • 128
    Flechsig E, Shmerling D, Hegyi I, Raeber AJ, Fischer M, Cozzio A, Von Mering C, Aguzzi A, Weissmann C. Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice. Neuron 2000; 27: 399408
  • 129
    Muramoto T, Scott M, Cohen FE, Prusiner SB. Recombinant scrapie-like prion protein of 106 amino acids is soluble. Proc Natl Acad Sci U S A 1996; 93: 1545762
  • 130
    Supattapone S, Bosque P, Muramoto T, Wille H, Aagaard C, Peretz D, Nguyen HOB, Heinrich C, Torchia M, Safar J, Cohen FE, DeArmond SJ, Prusiner SB, Scott M. Prion protein of 106 residues creates an artificial transmission barrier for prion replication in transgenic mice. Cell 1999; 96: 86978
  • 131
    Shmerling D, Hegyi I, Fischer M, Blättler T, Brandner S, Götz J, Rülicke T, Flechsig E, Cozzio A, Von Mering C, Hangartner C, Aguzzi A, Weissmann C. Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 1998; 93: 20314
  • 132
    Moore RC, Lee IY, Silverman GL, Harrison PM, Strome R, Heinrich C, Karunaratne A, Pasternak SH, Chishti MA, Liang Y, Mastrangelo P, Wang K, Smit AFA, Katamine S, Carlson GA, Cohen FE, Prusiner SB, Melton DW, Tremblay P, Hood LE, Westaway D. Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein Doppel. J Mol Biol 1999; 292: 797817
  • 133
    Silverman GL, Qin K, Moore RC, Yang Y, Mastrangelo P, Tremblay P, Prusiner SB, Cohen FE, Westaway D. Doppel is an N-glycosylated, glycosylphosphatidylinositol-anchored protein. J Biol Chem 2000; 275: 2683441
  • 134
    Rossi D, Cozzio A, Flechsig E, Klein MA, Rülicke T, Aguzzi A, Weissmann C. Onset of ataxia and Purkinje cell loss in PrP null mice inversely correlated with Dpl level in brain. EMBO J 2001; 20: 694702
  • 135
    Nishida N, Tremblay P, Sugimoto T, Shigematsu K, Shirabe S, Petromilli C, Erpel SP, Nakaoke R, Atarashi R, Houtani T, Torchia M, Sakaguchi S, DeArmond SJ, Prusiner SB, Katamine S. A mouse prion protein transgene rescues mice deficient for the prion protein gene from Purkinje cell degeneration and demyelination. Lab Invest 1999; 79: 68997
  • 136
    Weissmann C, Aguzzi A. Perspectives: neurobiology. PrP's double causes trouble. Science 1999; 286: 91415
  • 137
    Flechsig E, Weissmann C. The role of PrP in health and disease. Curr Mol Med 2004; 4: 33753
  • 138
    Watts JC, Drisaldi B, Ng V, Yang J, Strome B, Horne P, Sy MS, Yoong L, Young R, Mastrangelo P, Bergeron C, Fraser PE, Carlson GA, Mount HT, Schmitt-Ulms G, Westaway D. The CNS glycoprotein Shadoo has PrP(C)-like protective properties and displays reduced levels in prion infections. EMBO J 2007; 26: 403850
  • 139
    Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp H-P, DeArmond SJ, Prusiner SB, Aguet M, Weissmann C. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 1992; 356: 57782
  • 140
    Manson JC, Clarke A, Hooper ML, Aitchison L, McConnell I, Hope J. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol Neurobiol 1994; 8: 1217
  • 141
    Mallucci G, Ratté S, Asante E, Linehan J, Gowland I, Jefferys JGR, Collinge J. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J 2002; 21: 20210
  • 142
    Mallucci G, Dickinson A, Linehan J, Klohn P, Brandner S, Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 2003; 302: 8714
  • 143
    Mallucci G, Collinge J. Rational targeting for prion therapeutics. Nat Rev Neurosci 2005; 6: 2334
  • 144
    Westergard L, Christensen HM, Harris DA. The cellular prion protein (PrP(C) ): Its physiological function and role in disease. Biochim Biophys Acta 2007; 1772: 62944
  • 145
    Aguzzi A, Calella AM. Prions: protein aggregation and infectious diseases. Physiol Rev 2009; 89: 110552
  • 146
    Collinge J, Whittington MA, Sidle KCL, Smith CJ, Palmer MS, Clarke A, Jefferys JGR. Prion protein is necessary for normal synaptic function. Nature 1994; 370: 2957
  • 147
    Manson JC, Hope J, Clarke A, Johnston A, Black C, MacLeod N. PrP gene dosage and long term potentiation. Neurodegeneration 1995; 4: 11314
  • 148
    Tobler I, Gaus SE, Deboer T, Achermann P, Fischer M, Rulicke T, Moser M, Oesch B, McBride PA, Manson JC. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature 1996; 380: 63942
  • 149
    Colling SB, Collinge J, Jefferys JGR. Hippocampal slices from prion protein null mice: disrupted Ca2+-activated K+ currents. Neurosci Lett 1996; 209: 4952
  • 150
    Carleton A, Tremblay P, Vincent JD, Lledo PM. Dose-dependent, prion protein (PrP)-mediated facilitation of excitatory synaptic transmission in the mouse hippocampus. Pflugers Arch 2001; 442: 2239
  • 151
    Herms JW, Tings T, Dunker S, Kretzschmar HA. Prion protein affects Ca2+-activated K+ currents in cerebellar purkinje cells. Neurobiol Dis 2001; 8: 32430
  • 152
    Criado JR, Sanchez-Alavez M, Conti B, Giacchino JL, Wills DN, Henriksen SJ, Race R, Manson JC, Chesebro B, Oldstone MB. Mice devoid of prion protein have cognitive deficits that are rescued by reconstitution of PrP in neurons. Neurobiol Dis 2005; 19: 25565
  • 153
    Le Pichon CE, Valley MT, Polymenidou M, Chesler AT, Sagdullaev BT, Aguzzi A, Firestein S. Olfactory behavior and physiology are disrupted in prion protein knockout mice. Nat Neurosci 2009; 12: 609
  • 154
    Bremer J, Baumann F, Tiberi C, Wessig C, Fischer H, Schwarz P, Steele AD, Toyka KV, Nave KA, Weis J, Aguzzi A. Axonal prion protein is required for peripheral myelin maintenance. Nat Neurosci 2010; 13: 31018
  • 155
    Radovanovic I, Braun N, Giger OT, Mertz K, Miele G, Prinz M, Navarro B, Aguzzi A. Truncated prion protein and Doppel are myelinotoxic in the absence of oligodendrocytic PrPC. J Neurosci 2005; 25: 487988
  • 156
    Baumann F, Tolnay M, Brabeck C, Pahnke J, Kloz U, Niemann HH, Heikenwalder M, Rulicke T, Burkle A, Aguzzi A. Lethal recessive myelin toxicity of prion protein lacking its central domain. EMBO J 2007; 26: 53847
  • 157
    Li A, Christensen HM, Stewart LR, Roth KA, Chiesa R, Harris DA. Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105-125. EMBO J 2007; 26: 54858
  • 158
    Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 2006; 129: 224165
  • 159
    Nicoll AJ, Collinge J. Preventing prion pathogenicity by targeting the cellular prion protein. Infect Disord Drug Targets 2009; 9: 4857
  • 160
    Ghaemmaghami S, Ahn M, Lessard P, Giles K, Legname G, DeArmond SJ, Prusiner SB. Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog 2009; 5: e1000673
  • 161
    Telling GC, Scott M, Hsiao KK, Foster D, Yang S-L, Torchia M, Sidle KCL, Collinge J, DeArmond SJ, Prusiner SB. Transmission of Creutzfeldt-Jakob disease from humans to transgenic mice expressing chimeric human-mouse prion protein. Proc Natl Acad Sci U S A 1994; 91: 993640
  • 162
    Scott M, Groth D, Foster D, Torchia M, Yang SL, DeArmond SJ, Prusiner SB. Propagation of prions with artificial properties in transgenic mice expressing chimeric PrP genes. Cell 1993; 73: 97988
  • 163
    Mastrianni JA, Capellari S, Telling GC, Han D, Bosque P, Prusiner SB, DeArmond SJ. Inherited prion disease caused by the V210I mutation – Transmission to transgenic mice. Neurology 2001; 57: 2198205
  • 164
    Korth C, Kaneko K, Groth D, Heye N, Telling G, Mastrianni J, Parchi P, Gambetti P, Will R, Ironside J, Heinrich C, Tremblay P, DeArmond SJ, Prusiner SB. Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene. Proc Natl Acad Sci U S A 2003; 100: 47849
  • 165
    Manson JC, Jamieson E, Baybutt H, Tuzi NL, Barron R, McConnell I, Somerville R, Ironside J, Will R, Sy MS, Melton DW, Hope J, Bostock C. A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. EMBO J 1999; 18: 685564
  • 166
    Asano M, Mohri S, Ironside JW, Ito M, Tamaoki N, Kitamoto T. vCJD prion acquires altered virulence through trans-species infection. Biochem Biophys Res Commun 2006; 342: 2939
  • 167
    Bishop MT, Will RG, Manson JC. Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties. Proc Natl Acad Sci U S A 2010; 107: 1200510
  • 168
    Whittington MA, Sidle KCL, Gowland I, Meads J, Hill AF, Palmer MS, Jefferys JGR, Collinge J. Rescue of neurophysiological phenotype seen in PrP null mice by transgene encoding human prion protein. Nat Genet 1995; 9: 197201
  • 169
    Kobayashi A, Asano M, Mohri S, Kitamoto T. Cross-sequence transmission of sporadic Creutzfeldt-Jakob disease creates a new prion strain. J Biol Chem 2007; 282: 300228
  • 170
    Beringue V, Le Dur A, Tixador P, Reine F, Lepourry L, Perret-Liaudet A, Haik S, Vilotte JL, Fontes M, Laude H. Prominent and persistent extraneural infection in human PrP transgenic mice infected with variant CJD. PLoS ONE 2008; 3: e1419
  • 171
    Asante E, Linehan J, Gowland I, Joiner S, Fox K, Cooper S, Osiguwa O, Gorry M, Welch J, Houghton R, Desbruslais M, Brandner S, Wadsworth JD, Collinge J. Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice. Proc Natl Acad Sci U S A 2006; 103: 1075964
  • 172
    Hizume M, Kobayashi A, Teruya K, Ohashi H, Ironside JW, Mohri S, Kitamoto T. Human prion protein (PrP) 219K is converted to PrPSc but shows heterozygous inhibition in variant Creutzfeldt-Jakob disease infection. J Biol Chem 2009; 284: 36039
  • 173
    Mead S, Whitfield J, Poulter M, Shah P, Uphill J, Beck J, Campbell T, Al Dujaily H, Hummerich H, Alpers MP, Collinge J. Genetic susceptibility, evolution and the kuru epidemic. Philos Trans R Soc Lond B Biol Sci 2008; 363: 37416
  • 174
    Hosszu LL, Jackson GS, Trevitt C, Jones S, Batchelor M, Bhelt D, Prodromidou K, Clarke A, Waltho JP, Collinge J. The residue 129 polymorphism in human prion protein does not confer susceptibility to CJD by altering the structure or global stability of PrPC. J Biol Chem 2004; 279: 2851521
  • 175
    Riek R, Wider G, Billeter M, Hornemann S, Glockshuber R, Wuthrich K. Prion protein NMR structure and familial human spongiform encephalopathies. Proc Natl Acad Sci U S A 1998; 95: 1166772
  • 176
    Liemann S, Glockshuber R. Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein. Biochemistry 1999; 38: 325867
  • 177
    Hill AF, Joiner S, Beck J, Campbell TA, Dickinson A, Poulter M, Wadsworth JD, Collinge J. Distinct glycoform ratios of protease resistant prion protein associated with PRNP point mutations. Brain 2006; 129: 67685
  • 178
    Ashok A, Hegde RS. Selective processing and metabolism of disease-causing mutant prion proteins. PLoS Pathog 2009; 5: e1000479
  • 179
    Hornemann S, Von Schroetter C, Damberger FF, Wuthrich K. Prion protein-detergent micelle interactions studied by NMR in solution. J Biol Chem 2009; 284: 2271321
  • 180
    Van Der Kamp MW, Daggett V. The consequences of pathogenic mutations to the human prion protein. Protein Eng Des Sel 2009; 22: 4618
  • 181
    Parchi P, Chen SG, Brown P, Zou W, Capellari S, Budka H, Hainfellner J, Reyes PF, Golden GT, Hauw JJ, Gajdusek DC, Gambetti P. Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Sträussler-Scheinker disease. Proc Natl Acad Sci U S A 1998; 95: 83227
  • 182
    Furukawa H, Doh-ura K, Kikuchi H, Tateishi J, Iwaki T. A comparative study of abnormal prion protein isoforms between Gerstmann-Sträussler-Scheinker syndrome and Creutzfeldt-Jakob disease. J Neurol Sci 1998; 158: 715
  • 183
    Cardone F, Liu QG, Petraroli R, Ladogana A, D'Alessandro M, Arpino C, Di Bari M, Macchi G, Pocchiari M. Prion protein glycotype analysis in familial and sporadic Creutzfeldt-Jakob disease patients. Brain Res Bull 1999; 49: 42933
  • 184
    Piccardo P, Liepnieks JJ, William A, Dlouhy SR, Farlow MR, Young K, Nochlin D, Bird TD, Nixon RR, Ball MJ, DeCarli C, Bugiani O, Tagliavini F, Benson MD, Ghetti B. Prion proteins with different conformations accumulate in Geustmann-Straussler-Scheinker disease caused by A117V and F198S mutations. Am J Pathol 2001; 158: 22017
  • 185
    Tagliavini F, Lievens PMJ, Tranchant C, Warter JM, Mohr M, Giaccone G, Perini F, Rossi G, Salmona M, Piccardo P, Ghetti B, Beavis RC, Bugiani O, Frangione B, Prelli F. A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the major amyloid protein in Gerstmann-Straussler-Scheinker disease A117V. J Biol Chem 2001; 276: 600915
  • 186
    Asante EA, Gowland I, Grimshaw A, Linehan JM, Smidak M, Houghton R, Osiguwa O, Tomlinson A, Joiner S, Brandner S, Wadsworth JD, Collinge J. Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins. J Gen Virol 2009; 90: 54658
  • 187
    Gabizon R, Telling G, Meiner Z, Halimi M, Kahana I, Prusiner SB. Insoluble wild-type and protease-resistant mutant prion protein in brains of patients with inherited prion disease. Nat Med 1996; 2: 5964
  • 188
    Silvestrini MC, Cardone F, Maras B, Pucci P, Barra D, Brunori M, Pocchiari M. Identification of the prion protein allotypes which accumulate in the brain of sporadic and familial Creutzfeldt-Jakob disease patients. Nat Med 1997; 3: 5215
  • 189
    Chen SG, Parchi P, Brown P, Capellari S, Zou WQ, Cochran EJ, Vnencak-Jones CL, Julien J, Vital C, Mikol J, Lugaresi E, Autilio-Gambetti L, Gambetti P. Allelic origin of the abnormal prion protein isoform in familial prion diseases. Nat Med 1997; 3: 100915
  • 190
    Tateishi J, Kitamoto T. Inherited prion diseases and transmission to rodents. Brain Pathol 1995; 5: 539
  • 191
    Tateishi J, Kitamoto T, Hoque MZ, Furukawa H. Experimental transmission of Creutzfeldt-Jakob disease and related diseases to rodents. Neurology 1996; 46: 5327
  • 192
    Barron RM, Thomson V, Jamieson E, Melton DW, Ironside J, Will R, Manson JC. Changing a single amino acid in the N-terminus of murine PrP alters TSE incubation time across three species barriers. EMBO J 2001; 20: 50708
  • 193
    Hegde RS, Tremblay P, Groth D, DeArmond S, Prusiner SB, Lingappa VR. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 1999; 402: 8226
  • 194
    Chiesa R, Piccardo P, Quaglio E, Drisaldi B, Si-Hoe SL, Takao M, Ghetti B, Harris DA. Molecular distinction between pathogenic and infectious properties of the prion protein. J Virol 2003; 77: 761122
  • 195
    Chakrabarti O, Hegde RS. Functional depletion of mahogunin by cytosolically exposed prion protein contributes to neurodegeneration. Cell 2009; 137: 1136147
  • 196
    Hsiao KK, Scott M, Foster D, Groth DF, DeArmond SJ, Prusiner SB. Spontaneous neurodegeneration in transgenic mice with mutant prion protein. Science 1990; 250: 158790
  • 197
    Chiesa R, Piccardo P, Ghetti B, Harris DA. Neurological illness in transgenic mice expressing a prion protein with an insertional mutation. Neuron 1998; 21: 133951
  • 198
    Chiesa R, Pestronk A, Schmidt RE, Tourtellotte WG, Ghetti B, Piccardo P, Harris DA. Primary myopathy and accumulation of PrPSc-like molecules in peripheral tissues of transgenic mice expressing a prion protein insertional mutation. Neurobiol Dis 2001; 8: 27988
  • 199
    Harris DA, Chiesa R, Drisaldi B, Quaglio E, Migheli A, Piccardo P, Ghetti B. A murine model of a familial prion disease. Clin Lab Med 2003; 23: 17586
  • 200
    Muramoto T, DeArmond S, Scott M, Telling GC, Cohen FE, Prusiner SB. Heritable disorder reseming neuronal storage disease in mice expressing prion protein with deletion of an alpha-helix. Nat Med 1997; 3: 7505
  • 201
    Dossena S, Imeri L, Mangieri M, Garofoli A, Ferrari L, Senatore A, Restelli E, Balducci C, Fiordaliso F, Salio M, Bianchi S, Fioriti L, Morbin M, Pincherle A, Marcon G, Villani F, Carli M, Tagliavini F, Forloni G, Chiesa R. Mutant prion protein expression causes motor and memory deficits and abnormal sleep patterns in a transgenic mouse model. Neuron 2008; 60: 598609
  • 202
    Jackson WS, Borkowski AW, Faas H, Steele AD, King OD, Watson N, Jasanoff A, Lindquist S. Spontaneous generation of prion infectivity in fatal familial insomnia knockin mice. Neuron 2009; 63: 43850
  • 203
    Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, Torchia M, DeArmond SJ, Prusiner SB, Lingappa VR. A transmembrane from of the prion protein in neurodegenerative disease. Science 1998; 279: 82734
  • 204
    Hsiao KK, Groth D, Scott M, Yang S-L, Serban H, Rapp D, Foster D, Torchia M, DeArmond SJ, Prusiner SB. Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein. Proc Natl Acad Sci U S A 1994; 91: 9126130
  • 205
    Telling GC, Haga T, Torchia M, Tremblay P, DeArmond SJ, Prusiner SB. Interactions between wild-type and mutant prion proteins modulate neurodegeneration transgenic mice. Genes Dev 1996; 10: 173650
  • 206
    Westaway D, DeArmond SJ, Cayetano-Canlas J, Groth D, Foster D, Yang S-L, Torchia M, Carlson GA, Degeneration PSB. of skeletal muscle, peripheral nerves and the central nervous system in transgenic mice overexpressing wild-type prion proteins. Cell 1994; 76: 11729
  • 207
    Chiesa R, Piccardo P, Biasini E, Ghetti B, Harris DA. Aggregated, wild-type prion protein causes neurological dysfunction and synaptic abnormalities. J Neurosci 2008; 28: 1325867
  • 208
    Colby DW, Giles K, Legname G, Wille H, Baskakov IV, DeArmond SJ, Prusiner SB. Design and construction of diverse mammalian prion strains. Proc Natl Acad Sci U S A 2009; 106: 2041722
  • 209
    Butefisch CM, Gambetti P, Cervenakova L, Park KY, Hallett M, Goldfarb LG. Inherited prion encephalopathy associated with the novel PRNP H187R mutation: a clinical study. Neurology 2000; 55: 51722
  • 210
    Lysek DA, Nivon LG, Wuthrich K. Amino acid sequence of the Felis catus prion protein. Gene 2004; 341: 24953
  • 211
    Colucci M, Moleres FJ, Xie ZL, Ray-Chaudhury A, Gutti S, Butefisch CM, Cervenakova L, Wang W, Goldfarb LG, Kong Q, Ghetti B, Chen SG, Gambetti P. Gerstmann-Straussler-Scheinker: a new phenotype with ‘curly’ PrP deposits. J Neuropathol Exp Neurol 2006; 65: 64251
  • 212
    Wildegger G, Liemann S, Glockshuber R. Extremely rapid folding of the C-terminal domain of the prion protein without kinetic intermediates. Nat Struct Biol 1999; 6: 5503
  • 213
    Hart T, Hosszu LL, Trevitt CR, Jackson GS, Waltho JP, Collinge J, Clarke AR. Folding kinetics of the human prion protein probed by temperature jump. Proc Natl Acad Sci U S A 2009; 106: 56516
  • 214
    Asante E, Li YG, Gowland I, Jefferys JG, Collinge J. Pathogenic human prion protein rescues PrP null phenotype in transgenic mice. Neuroscience Lett 2004; 360: 336
  • 215
    Sigurdson CJ, Nilsson KP, Hornemann S, Heikenwalder M, Manco G, Schwarz P, Ott D, Rulicke T, Liberski PP, Julius C, Falsig J, Stitz L, Wuthrich K, Aguzzi A. De novo generation of a transmissible spongiform encephalopathy by mouse transgenesis. Proc Natl Acad Sci U S A 2009; 106: 3049
  • 216
    Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C. Darwinian evolution of prions in cell culture. Science 2010; 327: 86972
  • 217
    Brown P, Cathala F, Raubertas RF, Gajdusek DC, Castaigne P. The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature. Neurology 1987; 37: 895904
  • 218
    Mead S, Webb TE, Campbell TA, Beck J, Linehan J, Rutherfoord S, Joiner S, Wadsworth JD, Heckmann J, Wroe S, Doey L, King A, Collinge J. Inherited prion disease with 5-OPRI: phenotype modification by repeat length and codon 129. Neurology 2007; 69: 7308
  • 219
    Collins S, Law MG, Fletcher A, Boyd A, Kaldor J, Masters CL. Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet 1999; 353: 6937
  • 220
    Mahillo-Fernandez I, Pedro-Cuesta J, Bleda MJ, Cruz M, Molbak K, Laursen H, Falkenhorst G, Martinez-Martin P, Siden A. Surgery and risk of sporadic Creutzfeldt-Jakob disease in Denmark and Sweden: registry-based case-control studies. Neuroepidemiology 2008; 31: 22940
  • 221
    Pedro-Cuesta J, Mahillo-Fernandez I, Rabano A, Calero M, Cruz M, Siden A, Laursen H, Falkenhorst G, Molbak K. Nosocomial transmission of sporadic Creutzfeldt-Jakob disease: results from a risk-based assessment of surgical interventions. J Neurol Neurosurg Psychiatry 2010; E-pub Jun 14; doi:10.1136/jnnp.2009.188425 (Epub ahead of print)
  • 222
    Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S, Rossor M, Rudge P, Siddique D, Spyer M, Thomas D, Walker S, Webb T, Wroe S, Darbyshire J. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurology 2009; 2009: 33444
  • 223
    Lloyd S, Uphill JB, Targonski PV, Fisher E, Collinge J. Identification of genetic loci affecting mouse-adapted bovine spongiform encephalopathy incubation time in mice. Neurogenetics 2002; 4: 7781
  • 224
    Moreno CR, Lantier F, Lantier I, Sarradin P, Elsen JM. Detection of new quantitative trait loci for susceptibility to transmissible spongiform encephalopathies in mice. Genetics 2003; 165: 208591
  • 225
    Brown P, Preece MA, Will RG. ‘Friendly fire’ in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet 1992; 340: 247
  • 226
    Alpers MP. Epidemiology and clinical aspects of kuru. In Prions: Novel Infectious Pathogens Causing Scrapie and Creutzfeldt-Jakob Disease. Eds SBPrusiner, MPMcKinley. San Diego: Academic Press, 1987; 45165
  • 227
    Alpers MP. The epidemiology of kuru: monitoring the epidemic from its peak to its end. Philos Trans R Soc Lond B Biol Sci 2008; 363: 370713